Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Burning Rock Biotech (BNR) Current Deferred Revenue: 2019-2025

Historic Current Deferred Revenue for Burning Rock Biotech (BNR) over the last 1 years, with Jun 2025 value amounting to $102.8 million.

  • Burning Rock Biotech's Current Deferred Revenue was N/A to $102.8 million in Q2 2025 from the same period last year, while for Jun 2025 it was $102.8 million, marking a year-over-year change of. This contributed to the annual value of $16.2 million for FY2024, which is 12.15% down from last year.
  • Per Burning Rock Biotech's latest filing, its Current Deferred Revenue stood at $102.8 million for Q2 2025, which was up 536.45% from $16.2 million recorded in Q4 2024.
  • Burning Rock Biotech's Current Deferred Revenue's 5-year high stood at $102.8 million during Q2 2025, with a 5-year trough of $16.2 million in Q4 2024.
  • Over the past 3 years, Burning Rock Biotech's median Current Deferred Revenue value was $18.4 million (recorded in 2023), while the average stood at $45.8 million.
  • As far as peak fluctuations go, Burning Rock Biotech's Current Deferred Revenue spiked by 96.61% in 2021, and later declined by 14.10% in 2023.
  • Over the past 5 years, Burning Rock Biotech's Current Deferred Revenue (Quarterly) stood at $22.4 million in 2021, then decreased by 4.53% to $21.4 million in 2022, then fell by 14.10% to $18.4 million in 2023, then dropped by 12.15% to $16.2 million in 2024, then reached $102.8 million in 2025.
  • Its last three reported values are $102.8 million in Q2 2025, $16.2 million for Q4 2024, and $18.4 million during Q4 2023.